The Discounted Cash Flow (DCF) valuation of Biomarin Pharmaceutical Inc (BMRN) is 82.43 USD. With the latest stock price at 59.27 USD, the upside of Biomarin Pharmaceutical Inc based on DCF is 39.1%.
Based on the latest price of 59.27 USD and our DCF valuation, Biomarin Pharmaceutical Inc (BMRN) is a buy. buying Biomarin stocks now will result in a potential gain of 39.1%.
| Range | Selected | |
| WACC / Discount Rate | 6.3% - 8.1% | 7.2% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 53.65 - 199.44 | 82.43 |
| Upside | -9.5% - 236.5% | 39.1% |